ASRA Pain Medicine consensus practice infection control guidelines for regional anesthesia and pain medicine.

Background: To provide recommendations on risk mitigation, diagnosis and treatment of infectious complications associated with the practice of regional anesthesia, acute and chronic pain management.

Methods: Following board approval, in 2020 the American Society of Regional Anesthesia and Pain Medicine (ASRA Pain Medicine) commissioned evidence-based guidelines for best practices for infection control. More than 80 research questions were developed and literature searches undertaken by assigned working groups comprising four to five members.

Importance of Ultraviolet-C (UV-C) Emitter Configuration for the Attenuation of Staphylococcus aureus and Candida auris Pathogens.

Background: The relative importance of different ultraviolet-C (UV-C) emitter configurations on the attenuation of vegetative bacterial and fungal pathogens has not been assessed. We hypothesized that emitter configuration would impact the efficacy of UV-C attenuation of and ( pathogens.

Methods: American Type Culture Collection (ATCC) (ATCC 6538) and (ATCC MYA-5001 carriers (ReadyNowTM Test Carriers, Stratix Labs Corporation, Saint Paul, MN) were mounted on an aluminum stand along with three calibrated radiometers (International Light Technologies model ILT1270, Peabody, MA).

Importance of Ultraviolet-C (UV-C) Emitter Configuration for Clostridioides difficile Attenuation.

Background: The impact of ultraviolet-C (UV-C) emitter configuration on pathogen attenuation has not been assessed. We hypothesized that emitter configuration would impact UV-C efficacy for () attenuation.

Methods:  carriers (ReadyNow Test Carriers, Stratix Labs Corporation, Saint Paul, MN) inoculated with > 10 American Type Culture Collection (ATCC) 43593 (according to American Society for Testing and Materials (ASTM) 3135 standards) were obtained, and the following experiments were conducted from April to August of 2023.

A Randomized Placebo-Controlled Trial of Leronlimab in Mild-To-Moderate COVID-19.

Purpose: Early in the course of the SARS-CoV-2 pandemic it was hypothesised that host genetics played a role in the pathophysiology of COVID-19 including a suggestion that the CCR5-Δ32 mutation may be protective in SARS-CoV-2 infection. Leronlimab is an investigational CCR5-specific humanized IgG4 monoclonal antibody currently in development for HIV-1 infection. We aimed to explore the impact of leronlimab on the severity of disease symptoms among participants with mild-to-moderate COVID-19.